Trial results for the Navajo Community Outreach and Patient Empowerment (COPE) Program, which addresses multiple chronic conditions including hypertension, were posted on 2025-12-16. The program involved 28813 participants and showed varied impacts on key health markers, including a reduction in HbA1c and LDL, but an increase in systolic blood pressure.
Background
Chronic conditions such as diabetes mellitus, metabolic syndrome, and hypertension represent significant health challenges, particularly within specific communities. The Navajo Community Outreach and Patient Empowerment (COPE) Program was developed as a community-based strategy to address health disparities among Navajo individuals living with multiple chronic conditions. The program aims to improve health outcomes by targeting individual, family, and health system-level factors through coordinated efforts between community health representatives (CHRs) and Indian Health Service providers, standardized CHR training, a culturally-sensitive health promotion curriculum, and strong CHR supervision.
Trial design
This completed study evaluated the programmatic COPE strategy, enrolling a total of 28813 participants. The conditions investigated included Diabetes Mellitus, Metabolic Syndrome, Hypertension, and Chronic Disease. The trial compared outcomes for COPE participants against non-COPE participants, assessing the impact of the community-based intervention.
Key results
The study reported several key measurements and analyses:
- Change in Percentage of Glycated Hemoglobin (HbA1c): COPE participants showed a least squares mean change of -0.49 percent, while non-COPE participants showed a least squares mean change of 0.13 percent. This difference was statistically significant with a p-value of 0.0001.
- Change in Systolic Blood Pressure: COPE participants experienced a mean change of 1.43 mmHg, compared to 0.28 mmHg in non-COPE participants. This outcome had a p-value of 0.004.
- Change in Low-density Lipoprotein: COPE participants demonstrated a mean change of -8.04 mg/dl, while non-COPE participants showed a mean change of -3.21 mg/dl. The analysis yielded a p-value of 0.02.
- Change in Body Mass Index: COPE participants had a mean change of -0.25 kg/m^2, closely comparable to -0.26 kg/m^2 for non-COPE participants. The analysis for BMI change showed a p-value of 0.93.
- Change in Primary Outpatient Services: COPE participants showed a least squares mean change of 1.0750 number of visits per quarter post enroll, compared to 0.9224 number of visits per quarter post enroll for non-COPE participants. This was statistically significant with a p-value of 0.0091.
- Change in Specialty Outpatient Services: COPE participants had a least squares mean change of 0.8856 number of visits per quarter post enroll, versus 0.6838 number of visits per quarter post enroll for non-COPE participants. This difference was statistically significant with a p-value of 0.0003.
What this means
The Navajo COPE Program demonstrated a complex impact on chronic disease markers and healthcare utilization. Positive outcomes were observed in the reduction of HbA1c and LDL levels among COPE participants, suggesting a beneficial effect on diabetes and lipid management. However, an increase in systolic blood pressure for COPE participants compared to non-COPE participants indicates a less favorable outcome for hypertension management in this specific measure. The program also led to a statistically significant increase in both primary and specialty outpatient services for COPE participants, which could reflect increased engagement with the healthcare system, potentially due to enhanced coordination and patient empowerment, or increased need for care. The lack of significant difference in BMI change between groups suggests no substantial impact on weight management.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT03326206, titled "Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program", were posted on 2025-12-16 on clinicaltrials.gov.